Sumitomo Pharma America
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sumitomo Pharma America sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Sumitomo Pharma America: 168 sponsored US clinical trials, 6 recruiting.
Sumitomo Pharma America sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 142 completed. 83 of these trials are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 4 trials.
Top-decile sponsor footprint
Sumitomo Pharma America ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 159 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 2 of 4
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
NCT02483247
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
NCT02491073
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
NCT02542696
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
NCT02467361
Dasotraline Pediatric Extension Study
NCT02457819
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
NCT02469090
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
NCT02432690
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
NCT02352558
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
NCT02432326
Dasotraline Pediatric ADHD Study
NCT02428088
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
NCT02315534
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
NCT02279719
Dasotraline Adult ADHD Study
NCT02276209
A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT02275481
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
NCT02178956
A Study to Examine APL-130277 in Patients With Parkinson's Disease
NCT02228590
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
NCT02231723
Dasotraline SEP360-105 Pediatric PK/PD Study
NCT02195167
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
NCT02150499
Open-label Safety Study in Adults With ADHD
NCT02160262
Lurasidone Pediatric Bipolar Study
NCT02046369
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
NCT02024607
Pediatric Open-Label Extension Study
NCT01914393
Pediatric Schizophrenia Efficacy and Safety Study
NCT01911429
Lurasidone Pediatric Autism Study
NCT01911442
Lurasidone Low-Dose - High-Dose Study Study
NCT01821378
Adult Attention Deficit Hyperactivity Disorder
NCT01692782
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
NCT01774747
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
NCT01654536
Clinical Study of WT2725 in Patients With Advanced Malignancies
NCT01621542
This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
NCT01575561
Lurasidone Pediatric Pharmacokinetics Study
NCT01620060
A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
NCT01566162
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
NCT01776307
A Study of BBI503 in Adult Patients With Advanced Solid Tumors
NCT01781455
A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects
NCT01531972
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
NCT01458275
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
NCT01451541
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
NCT01421134
Major Depressive Disorder With Mixed Features - Extension
NCT01423253
PEARL Schizophrenia Maintenance
NCT01435928
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
NCT01378429
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
NCT01401465
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
NCT01358357
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
NCT01325441
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
NCT01287364
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
NCT01284517
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT01143090
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
NCT01143077
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
NCT01091662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 27 |
| Phase 3 | 75 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Sumitomo Pharma America pipeline
6 recruiting of 168 indexed (4% open); 142 completed (85%).
Phase mix: 83 late (III/IV) vs 80 early (I/II) (balanced across stages).
Top condition: Schizophrenia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sumitomo Pharma America: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Sumitomo Pharma America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Bausch Health Americas · 168 trials · 4% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Sumitomo Pharma America page
168 registered trials is a research-attention snapshot, not an endorsement of Sumitomo Pharma America or any single study.
- 6 of Sumitomo Pharma America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Sumitomo Pharma America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sumitomo Pharma America pipeline card: 168 registered trials from official public datasets.Report a data error.